RxDoctor Payments Data

Jonathan Parrott, MD

Emergency Medicine · Valdosta, GANPI 1962470385

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 136 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AstraZeneca at 47.5% of the total. Reporting peaked in 2019 at $527 and has fallen 52.4% since, to $251 in 2025. Among emergency medicine clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,394in general payments, 2019–2025

Across 136 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$742
  • Genentech USA, Inc.$140
  • Amgen$102
  • Lilly USA, LLC$85
  • Eisai Inc.$53
  • plus $135 from 4 others

What the payments were for

  • Food & beverage$2,394100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,394 in reported general payments places this provider in the 95th percentile of 1,299 emergency medicine providers in Georgia.

See all emergency medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$56,130
Medicare patients
325
Services billed
1,352

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,025
Oseltamivir Phosphate39$723
Montelukast Sodium112$710
Azithromycin204$701
Prednisone328$639
Bisoprolol-HydrochlorothiazideBisoprolol/Hydrochlorothiazide19$419
Amlodipine Besylate41$367
Albuterol Sulfate HfaAlbuterol Sulfate11$360
Cefdinir27$358
Allopurinol12$335
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav36$328
Fluconazole38$274
Doxycycline Hyclate31$264
Atorvastatin Calcium35$244
Fenofibrate16$233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere$1,136$7,02511 claims
PfizerPaxlovid$30$017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,299 emergency medicine providers in Georgia.

Other emergency medicine in Valdosta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →